Lilly plans to create 3,000 jobs for skilled workers at four new sites. The company is expanding its medicine production in the US by building new manufacturing facilities. Since 2020, Lilly has invested over $50 billion in US expansions. Three of the new sites will focus on making key chemical ingredients to strengthen the supply chain. The fourth site will support the production of injectable medicines.
The construction of these sites will provide about 10,000 jobs, and once completed, the facilities will employ 3,000 professionals including operations staff, scientists, lab technicians, and engineers. These sites will benefit local communities by boosting the economy, creating job training opportunities, and enhancing infrastructure.
Lilly’s president of manufacturing, Edgardo Hernandez, emphasized the company’s commitment to building advanced facilities for future medicines and supporting a skilled workforce to drive innovation in pharmaceutical manufacturing.
Between 2020 and 2024, Lilly has committed $23 billion to expanding in the US, part of the $50 billion total investment. This includes investments in locations like North Carolina, Indiana, and Wisconsin, as well as the opening of a research center in Boston in 2024.